Product Description | Brain natriuretic peptide (type B natriuretic peptide, BNP) was originally isolated from brain, but is mainly produced in myoendocrine cells of the heart ventricles from which it is released into the circulatory ststem. Its 32 amino acid peptide contains a 17 amino acid ring structure that is common to all natriuretic peptides. It has natriuretic and vasodilatory effects and suppresses the renin-angiotensin-aldosterone system. |
Scientific Background | BNP-32, human is a 34-residue synthetic peptide with the sequence Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-Cys-Cys. The sequence contains 4 cysteine residues, providing potential thiol/disulfide chemistry when the thiol is available; contains 3 Lys and 4 Arg residues, contributing cationic character. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
